Dr. Joshua Ok. Sabari and Dr. Nausheen Ahmed sat down to debate topline takeaways within the realm of hematologic malignancies following the 2025 ASCO Annual Assembly, highlighting what sufferers ought to know following the assembly.
“We had an awesome ASCO Assembly [with updates across] the myeloma and lymphoma fields. I’m going to spotlight a number of the a number of the research that had been offered that had been [most] fascinating,” Ahmed started.
To kick issues off, Ahmed highlighted the section 3 PERSEUS trial which evaluated transplant-eligible sufferers with newly recognized a number of myeloma, and within the examine, investigators evaluated remedy with subcutaneous Darzalex (daratumumab) plus Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone and Revlimid upkeep versus commonplace Velcade, Revlimid, and dexamethasone. The trial confirmed an enchancment in stringent full response and minimal residual illness (MRD) negativity with the examine routine in contrast with commonplace of care.
Ahmed continued by relating the ADVANCE trial within the transplant-eligible, newly recognized myeloma affected person inhabitants. The examine evaluated remedy with Kyprolis (carfilzomib), Revlimid, and dexamethasone with or with out Darzalex (daratumumab), discovering that the investigative remedy confirmed a statistically vital enchancment in minimal residual illness negativity, with no new security alerts.
She additionally touched on key takeaways within the lymphoma affected person inhabitants, highlighting mobile therapies particularly. Ahmed highlighted the section 1 examine of KITE-363, an anti-CD19/CD20 CAR-T cell remedy for these with relapsed/refractory B -cell lymphoma. Investigators discovered that using the therapeutic had a positive security and efficacy profile, and demonstrated a possible position as a next-generation CAR T product.
“Thanks, Dr. Ahmed,” Dr. Sabari concluded. “That was a wonderful and exhaustive checklist of various abstracts offered at ASCO 2025. It is nice to listen to that the variety of therapies being developed and accepted for our sufferers with hematologic malignancies. Thanks for becoming a member of us and thanks for imparting your knowledge on our CURE readership.”
Ahmed is a board-certified hematologist and affiliate professor, Hematologic Malignancies and Mobile Therapeutics, at The College of Kansas, KU Medical Middle. Sabari is the editor in chief of CURE. He additionally serves as an assistant professor within the Division of Medication at NYU Grossman Faculty of Medication and director of Excessive Reliability Group Initiatives at Perlmutter Most cancers Middle.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
